J Vasc Surg. 1984 Sep;1(5):608-16.
Postoperative pulmonary embolism continues to be a problem in patient care, especially in high-risk patients. This study was designed to evaluate a combined pharmacologic approach to the prophylaxis of postoperative deep venous thrombosis (DVT) by mediating at least two and probably three of Virchow's predisposing factors. Patients 40 years of age and older undergoing operations greater than 45 minutes under general anesthesia were placed in one of five treatment groups and studied by a prospective randomized, double-blind protocol. Study drugs were the following: (1) 0.5 mg of dihydroergotamine plus 5000 IU of sodium heparin (DHE 5000), (2) 0.5 mg DHE plus 2500 IU heparin (DHE 2500), (3) 5000 IU of HEP (HEP 5000), (4) 0.5 mg of DHE (DHE 0.5), and (5) a placebo. Study medications were administered 2 hours preoperatively and continuously thereafter every 12 hours postoperatively subcutaneously in the anterior abdominal wall for 5 to 7 days or until a positive radiofibrinogen uptake test (RFUT). The RFUT was performed according to standardized technique and was used to establish the presence or absence of DVT. This report is an analysis of the major subgroup of patients undergoing intra-abdominal operations. Results showed a highly statistically significant prophylactic benefit from DHE 5000 compared with the placebo (p less than 0.003) and all other treatment groups (p less than 0.05). There was no significant benefit from DHE 2500, HEP 5000 (p greater than 0.13), and DHE 0.5 (p greater than 0.3). All patients who entered the study had two or more risk factors for postoperative DVT, and high-risk patients were distributed equally throughout all treatment groups.(ABSTRACT TRUNCATED AT 250 WORDS)
术后肺栓塞仍是患者护理中的一个问题,尤其是在高危患者中。本研究旨在评估一种联合药物预防方法,通过调节至少两个且可能三个维勒氏易患因素来预防术后深静脉血栓形成(DVT)。40岁及以上接受全身麻醉下超过45分钟手术的患者被分为五个治疗组之一,并采用前瞻性随机双盲方案进行研究。研究药物如下:(1)0.5毫克双氢麦角胺加5000国际单位肝素钠(DHE 5000),(2)0.5毫克双氢麦角胺加2500国际单位肝素(DHE 2500),(3)5000国际单位肝素(HEP 5000),(4)0.5毫克双氢麦角胺(DHE 0.5),以及(5)安慰剂。研究药物在术前2小时给药,此后在术后每12小时在前腹壁皮下连续给药5至7天,或直至放射性纤维蛋白原摄取试验(RFUT)呈阳性。RFUT按照标准化技术进行,用于确定是否存在DVT。本报告是对接受腹部手术患者主要亚组的分析。结果显示,与安慰剂相比,DHE 5000具有高度统计学意义的预防益处(p<0.003),与所有其他治疗组相比也有显著益处(p<0.05)。DHE 2500、HEP 5000(p>0.13)和DHE 0.5(p>0.3)没有显著益处。所有进入研究的患者都有两个或更多术后DVT的危险因素,高危患者在所有治疗组中分布均匀。(摘要截短至250字)